Table 4. Immunogenicity of optimized HLA-B*0702 restricted peptides and cross recognition of the native peptides.
| Antigen | Peptide | Sequence | Immunogenicity against optimized peptide | Immunogenicity against native peptide |
|---|---|---|---|---|
| HER2/neu | HER2/neu246A1 | APKHSDCLA | 8/12 | 5/12 |
| MAGE-A | MAGE-A274 L9 | GPRALVETL | 18/18 | MAGE-A1267 3/8 MAGE-A2274 3/5 MAGE-A3274 4/5 |
| CEA | CEA188L9 | SPRLQLSNL | 6/6 | 6/6 |
HLA-B*0702 mice were vaccinated twice with the optimized peptides. Specific CTLs were detected by cytotoxicity or IFNγ ELISPOTs against target cells loaded with the optimized peptide or the native peptide, results are presented as number of responding mice/number of vaccinated mice.